Artelo Biosciences, INC Form 4 insider transactions

Connie Matsui, a Director of Artelo Biosciences, Inc., received 136 shares of common stock on 2026-07-17-05:00.

Douglas Blayney, a Director of Artelo Biosciences, Inc., received 136 shares of common stock on 2026-07-17-05:00.

Gregory Reyes, a Director of Artelo Biosciences, Inc., received 136 shares of common stock on 2026-07-17-05:00.

Robert Martin Emanuele, a Director of Artelo Biosciences, Inc., received 136 shares of common stock on 2026-07-17-05:00.

Steven Kelly, a Director of Artelo Biosciences, Inc., received 136 shares of common stock on 2026-07-17-05:00.

Tamara A Favorito, a Director of Artelo Biosciences, Inc., received 136 shares of common stock on 2026-07-17-05:00.

Artelo Biosciences Director Connie Matsui acquired 292 stock options with an exercise price of $1.71, vesting on January 30, 2027, or earlier.

ARTELO BIOSCIENCES Director Douglas Blayney was granted 292 stock options with an exercise price of $1.71, vesting on January 30, 2027, or earlier.

ARTELO BIOSCIENCES, INC. Director Robert Martin Emanuele was granted 292 stock options with an exercise price of $1.71, vesting on January 30, 2026.

ARTELO BIOSCIENCES, INC. Director Steven Kelly was granted 292 stock options with an exercise price of $1.71, vesting on January 30, 2027, or earlier.

ARTELO BIOSCIENCES Director Tamara A Favorito received a grant of 292 stock options with an exercise price of $1.71, set to vest based on service.

ARTELO BIOSCIENCES, INC. Director Gregory Reyes was granted 292 stock options with an exercise price of $1.71, vesting over one year.

ARTELO BIOSCIENCES' Chief Financial Officer, Mark Edward Spring, acquired 36,391 stock options with an exercise price of $1.68, vesting over four years.

ARTELO BIOSCIENCES, INC. CEO Gregory D. Gorgas was granted 154,713 stock options with an exercise price of $1.68, vesting over four years.

Artelo Biosciences director Connie Matsui converted a portion of a convertible promissory note into warrants and reinvested the remainder into a new convertible note and additional warrants.

ARTELO BIOSCIENCES Director Tamara A. Favorito converted a portion of a convertible promissory note into warrants and reinvested the remainder into a new note and additional warrants.

ARTELO Biosciences CEO Gregory Gorgas converted a portion of a convertible promissory note into warrants and reinvested the remainder into a new convertible note and additional warrants.

ARTELO BIOSCIENCES, INC. disclosed that its President, CEO, CFO, and Treasurer, Gregory D. Gorgas, was granted 40,393 stock options with an exercise price of $11.03, subject to multi-year vesting schedules.

Director Tamara A. Favorito acquired a convertible promissory note from Artelo Biosciences, Inc. on May 1, 2025, which may be converted into common stock or warrants.

Connie Matsui, a director at Artelo Biosciences, acquired a convertible promissory note for $140,000 on May 1, 2025, which may be converted into common stock or warrants.

Gregory D. Gorgas, CEO of Artelo Biosciences, acquired a convertible promissory note from the company on May 1, 2025.

Connie Matsui, a director of Artelo Biosciences, acquired stock options exercisable for 1,750 shares of common stock on December 20, 2024.

Director Douglas Blayney acquired stock options in Artelo Biosciences on December 20, 2024.

Gregory Reyes, a director at Artelo Biosciences, acquired stock options for 1,750 shares on December 20, 2024.

Director Robert Martin Emanuele acquired stock options in Artelo Biosciences, Inc. on December 20, 2024.

Director Steven Kelly acquired stock options in Artelo Biosciences, Inc. on December 20, 2024.

Director Tamara A. Favorito acquired stock options in Artelo Biosciences, Inc. on December 20, 2024.

Director Tamara Favorito reports transactions involving stock options in Artelo Biosciences, including repricing and revesting of existing options and acquisition of new options.

Director Emanuele Robert Martin reports adjustments to stock options in Artelo Biosciences, including repricing and revesting.

Director Kelly Steven reports adjustments to stock option holdings in Artelo Biosciences, including repricing and revesting of certain options.